Pages that link to "Q72698798"
Jump to navigation
Jump to search
The following pages link to Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease (Q72698798):
Displaying 29 items.
- The benefits and risks of bacille Calmette-Guérin vaccination among infants at high risk for both tuberculosis and severe combined immunodeficiency: assessment by Markov model. (Q33235419) (← links)
- Beyond BCG: the potential for a more effective TB vaccine (Q33756046) (← links)
- Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness (Q34514165) (← links)
- Tuberculosis 2004: challenges and opportunities (Q34655115) (← links)
- Pediatric tuberculosis in Alberta First Nations (1991-2000): outbreaks and the protective effect of bacille Calmette-Guérin (BCG) vaccine. (Q35885029) (← links)
- Revised guidelines for the diagnosis and control of tuberculosis: impact on management in the elderly (Q36214730) (← links)
- BCG vaccination in England since 2005: a survey of policy and practice (Q36307004) (← links)
- The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Guérin (BCG) vaccines: is there a link? (Q36565187) (← links)
- Evaluating the neonatal BCG vaccination programme in Ireland (Q37089990) (← links)
- Trend of application of World Health Organization control strategy of tuberculosis in Egypt. (Q38238323) (← links)
- Do selective immunisation against tuberculosis and hepatitis B reach the targeted populations? A nationwide register-based study evaluating the recommendations in the Norwegian Childhood Immunisation Programme (Q38395140) (← links)
- Performance of QuantiFERON(®)-TB Gold In-Tube assay in children receiving disease modifying anti-rheumatic drugs (Q40159900) (← links)
- Mycobacterium tuberculosis infection in First Nations preschool children in Alberta: implications for BCG (bacille Calmette-Guérin) vaccine withdrawal. (Q40222237) (← links)
- Stopping routine vaccination for tuberculosis in schools (Q43006538) (← links)
- Assessing the impact of different BCG vaccination strategies on severe childhood TB in low-intermediate prevalence settings (Q45164225) (← links)
- Decrease in the incidence of culture-positive meningitis and cerebral tuberculomas in France from 1990 to 2007. (Q45245023) (← links)
- Tuberculosis in the Bajo Deba area (Guipúzcoa, Spain) from 1995 to 2006 (Q46670421) (← links)
- Estimation of the epidemiological impact of various BCG vaccination scenarios in France (Q50776197) (← links)
- The Tuberculin Skin Test Is Unreliable in School Children BCG-vaccinated in Infancy and at Low Risk of Tuberculosis Infection (Q51040300) (← links)
- BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay (Q51812819) (← links)
- A false economy: we cannot afford to be complacent when it comes to tuberculosis control. (Q54274514) (← links)
- The Necessity of a Nationwide Surveillance System of Serious BCG Adverse Reactions (Q60922166) (← links)
- [BCG and tuberculin tests: evolutions of French vaccinal policy] (Q73702772) (← links)
- [SEPAR guidelines. Guidelines for tuberculosis prevention] (Q74800631) (← links)
- [What place for BCG vaccination in France?] (Q77691883) (← links)
- [BCG Today] (Q79331088) (← links)
- [Evaluation of clinical practice in pulmonology: tuberculosis] (Q79487596) (← links)
- [Tuberculosis. Spain is different and the oblivion of the BCG vaccine] (Q82838981) (← links)
- Modelling the effect of discontinuing universal Bacillus Calmette-Guérin vaccination in an intermediate tuberculosis burden setting (Q91131260) (← links)